Class Action Cases

Attorneys

OvaScience, Inc

Rosen Law Firm announces the filing of a securities class action lawsuit on behalf of purchasers of OvaScience, Inc. securities (NASDAQ: OVAS) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with OvaScience’s January 8, 2015 Secondary Offering, resulting from allegations that Cigna may have issued materially misleading business information to the investing public.

If you purchased shares of OvaScience pursuant to and/or traceable to OvaScience’s January 8, 2015 Secondary Offering and would like to join the action, please click "Join This Class Action" above.

Press Release

New York, N.Y., February 10, 2016. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of OvaScience, Inc. securities (NASDAQ: OVAS) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with OvaScience’s January 8, 2015 Secondary Offering (the “Offering”). The lawsuit seeks to recover damages for OvaScience investors under the federal securities laws.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, the documents filed in connection with the Offering contained materially false and misleading statements and omissions, including that the approximately 150 patients that had received OvaScience’s AUGMENT procedure in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without its AUGMENT procedure. When the true details entered the market, the lawsuit claims that investors suffered damages.